NOVEN
ANNOUNCES AVAILABILITY OF CLINICAL DATA |
BackMiami, FL, May 1,
2003 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
the availability of clinical data examining the effects of transdermal
combination hormone replacement therapy (HRT) on the sexual quality
of life of postmenopausal women and on renin substrate levels, which
may impact blood pressure.
Separate posters entitled "CombiPatch® Significantly
Improves Women's Sexual Quality of Life Compared to Prempro™ in
a Randomized Trial" and "Renin Substrate Levels
Decrease With Transdermal Hormone Therapy and Increase With Oral Hormone
Therapy" were
recently presented at a national medical conference. The data was presented
by James A. Simon M.D., of George Washington University; Rebecca G.
Rogers, M.D., of the University of New Mexico; and Vanaja V. Rgavan
M.D., of Novartis Pharmaceuticals Corporation. Copies of the poster
presentations are available at www.noven.com under "Research
– Scientific Publications".
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a
leading developer of advanced transdermal drug delivery technologies
and prescription transdermal products, including the only combination
HRT patch available in the United States. For additional information
on Noven, visit www.noven.com. Prempro™ is a registered trademark
of Wyeth Pharmaceuticals; CombiPatch® is a registered trademark
of Novogyne Pharmaceuticals.
Contact:
Investor & Media Contact
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916
Copyright © 2003 Noven Pharmaceuticals, Inc. All rights reserved.